These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 9561951)

  • 1. The impact of depression on the outcome of addictions treatment.
    Charney DA; Paraherakis AM; Negrete JC; Gill KJ
    J Subst Abuse Treat; 1998; 15(2):123-30. PubMed ID: 9561951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Integrated treatment of comorbid depression and substance use disorders.
    Charney DA; Paraherakis AM; Gill KJ
    J Clin Psychiatry; 2001 Sep; 62(9):672-7. PubMed ID: 11681761
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treating depression and substance use: a randomized controlled trial.
    Hunter SB; Watkins KE; Hepner KA; Paddock SM; Ewing BA; Osilla KC; Perry S
    J Subst Abuse Treat; 2012 Sep; 43(2):137-51. PubMed ID: 22301087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association between improvement in depression, reduced benzodiazepine (BDZ) abuse, and increased psychotropic medication use in methadone maintenance treatment (MMT) patients.
    Schreiber S; Peles E; Adelson M
    Drug Alcohol Depend; 2008 Jan; 92(1-3):79-85. PubMed ID: 17706374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosing major depression in cocaine abusers: the use of depression rating scales.
    Weiss RD; Griffin ML; Mirin SM
    Psychiatry Res; 1989 Jun; 28(3):335-43. PubMed ID: 2762434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized effectiveness trial of interpersonal psychotherapy for depressed adolescents.
    Mufson L; Dorta KP; Wickramaratne P; Nomura Y; Olfson M; Weissman MM
    Arch Gen Psychiatry; 2004 Jun; 61(6):577-84. PubMed ID: 15184237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The management of treatment resistance in depressed patients with substance use disorders.
    Nunes EV; Deliyannides D; Donovan S; McGrath PJ
    Psychiatr Clin North Am; 1996 Jun; 19(2):311-27. PubMed ID: 8827192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Posttraumatic stress disorder's role in integrated substance dependence and depression treatment outcomes.
    Norman SB; Tate SR; Wilkins KC; Cummins K; Brown SA
    J Subst Abuse Treat; 2010 Jun; 38(4):346-55. PubMed ID: 20363091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of two depressive symptomatology measures in residential substance abuse treatment clients.
    Hepner KA; Hunter SB; Edelen MO; Zhou AJ; Watkins K
    J Subst Abuse Treat; 2009 Oct; 37(3):318-25. PubMed ID: 19359127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effects of substance use disorder on the clinical presentation of anxiety and depression in an outpatient psychiatric clinic.
    Tsuang D; Cowley D; Ries R; Dunner DL; Roy-Byrne PP
    J Clin Psychiatry; 1995 Dec; 56(12):549-55. PubMed ID: 8530330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treating depressed primary care patients improves their physical, mental, and social functioning.
    Coulehan JL; Schulberg HC; Block MR; Madonia MJ; Rodriguez E
    Arch Intern Med; 1997 May; 157(10):1113-20. PubMed ID: 9164377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of anxiety and depression on completion/withdrawal status in patients admitted to substance abuse detoxification program.
    Araujo L; Goldberg P; Eyma J; Madhusoodanan S; Buff DD; Shamim K; Brenner R
    J Subst Abuse Treat; 1996; 13(1):61-6. PubMed ID: 8699544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acupuncture treatment for women with concurrent substance use and anxiety/depression: an effective alternative therapy?
    Courbasson CM; de Sorkin AA; Dullerud B; Van Wyk L
    Fam Community Health; 2007; 30(2):112-20. PubMed ID: 19241647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluoxetine versus placebo in depressed alcoholic cocaine abusers.
    Cornelius JR; Salloum IM; Thase ME; Haskett RF; Daley DC; Jones-Barlock A; Upsher C; Perel JM
    Psychopharmacol Bull; 1998; 34(1):117-21. PubMed ID: 9564208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The treatment of sedative-hypnotic dependence: evaluating clinical predictors of outcome.
    Charney DA; Paraherakis AM; Gill KJ
    J Clin Psychiatry; 2000 Mar; 61(3):190-5. PubMed ID: 10817104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Major depression in patients with substance use disorders: relationship to 12-Step self-help involvement and substance use outcomes.
    Kelly JF; McKellar JD; Moos R
    Addiction; 2003 Apr; 98(4):499-508. PubMed ID: 12653819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The moderating effects of group cognitive-behavioral therapy for depression among substance users.
    Hunter SB; Witkiewitz K; Watkins KE; Paddock SM; Hepner KA
    Psychol Addict Behav; 2012 Dec; 26(4):906-16. PubMed ID: 22564202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential response to cognitive therapy in parolees with primary and secondary substance use disorders.
    Nishith P; Mueser KT; Srsic CS; Beck AT
    J Nerv Ment Dis; 1997 Dec; 185(12):763-6. PubMed ID: 9442189
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparing the BDI-II and the PHQ-9 with outpatient substance abusers.
    Dum M; Pickren J; Sobell LC; Sobell MB
    Addict Behav; 2008 Feb; 33(2):381-7. PubMed ID: 17964079
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recognition and management of depression in a substance use disorder treatment population.
    Curran GM; Booth BM; Kirchner JE; Deneke DE
    Am J Drug Alcohol Abuse; 2007; 33(4):563-9. PubMed ID: 17668342
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.